Is Agenus, Inc. overvalued or undervalued?

As of 8 November 2022, the valuation grade for Agenus, Inc. moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered undervalued, primarily due to its negative financial metrics. Key ratios include a Price to Book Value of -0.48, an EV to EBIT of -4.84, and an EV to EBITDA of -5.54, all of which highlight the challenges the company faces.
When compared to its peers, Agenus shows a P/E ratio of -0.6631, while Avidity Biosciences, Inc. has a P/E of -9.5851 and Janux Therapeutics, Inc. stands at -17.5680, suggesting that Agenus is relatively better positioned among its risky counterparts. Despite the recent stock performance showing a year-to-date return of 75.18%, it has still underperformed significantly over longer periods, such as a one-year decline of 67.03% compared to a 10.26% return for the S&P 500. This context reinforces the notion that Agenus may be undervalued in the current market landscape.